Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | PTAFR | P25105 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16869651 | 1.00 | NAMPT (1.00) | NAMPTROCK2ROCK1PTAFRNPC1 | |
| SCHEMBL18270182 | 0.92 | NAMPT (0.86) | NAMPTROCK2ROCK1PTAFRNPC1 | |
| SCHEMBL16869603 | 0.91 | NAMPT (0.84) | NAMPTROCK2ROCK1PTAFR | |
| SCHEMBL22212144 | 0.90 | NAMPT (0.82) | NAMPTROCK2ROCK1NPC1RAB9A | |
| SCHEMBL16869511 | 0.89 | NAMPT (0.81) | NAMPTROCK2ROCK1PTAFRNPC1 | |
| SCHEMBL18270220 | 0.89 | NAMPT (0.81) | NAMPTROCK2ROCK1 | |
| SCHEMBL31037330 | 0.87 | NAMPT (0.77) | NAMPTROCK2ROCK1 | |
| SCHEMBL16869638 | 0.86 | NAMPT (0.76) | NAMPTROCK2ROCK1 | |
| SCHEMBL18270171 | 0.86 | NAMPT (0.75) | NAMPTROCK2ROCK1PTAFR | |
| SCHEMBL22212213 | 0.85 | NAMPT (0.74) | NAMPTROCK2ROCK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| WO-2025099152-A1 | ANTIBODIES AND MOLECULAR CONJUGATES THEREOF TARGETING UPAR | RIGSHOSPITALET (DK) | 2025-05-15 | — | — | WO | claimed |
| EP-4363447-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | Rigshospitalet (DK) | 2024-05-08 | — | — | EP | claimed |
| CN-117751140-A | Antibody-drug conjugates comprising humanized antibodies targeting urokinase-type plasminogen activator receptor-related protein (uPARAP) | 丹麦国家医院 | 2024-03-22 | — | — | CN | claimed |
| WO-2023275112-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2023-01-05 | — | — | WO | claimed |
| US-20220062260-A1 | COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS | NEW YORK UNIVERSITY | 2022-03-03 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | disclosed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025106716-A2 | ANTI-NAPRT ANTIBODIES AND METHODS OF USE | ALPHINA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-11944615-B2 | Combination therapy for treatment of LKB1 deficient cancers | NEW YORK UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-117751140-A | Antibody-drug conjugates comprising humanized antibodies targeting urokinase-type plasminogen activator receptor-related protein (uPARAP) | 丹麦国家医院 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023172805-A1 | METHODS AND COMPOSITIONS FOR PRODUCING TOBACCO PLANTS WITH REDUCED NICOTINIC ALKALOID LEVELS | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023158783-A2 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023275112-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2023-01-05 | — | — | WO | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220062260-A1 | COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS | NEW YORK UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | NAMPT 1/4885ROCK2 1271/4885ROCK1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.